NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

Since you are adamantly certain of your position, perhaps you might kindly provide US case citations supporting your position. I, for one, would appreciate learning something new.

Indeed an immense number of posts have been dedicated to the subject and I have had my share of conversations on the subject. Look. NWBO is a one product small biotech with its financial future totally depending on that single product. The whole company and stock price depend on it.
https://www.investopedia.com/terms/1/8-k.asp

The SEC requires disclosure for numerous changes relating to a registrant's business and operations. Changes to a material definitive agreement or the bankruptcy of an entity must be reported. Other financial information disclosure requirements include the completion of an acquisition, changes in the firm's financial condition, disposal activities, and substantial impairments. The SEC mandates filing an 8-K for the delisting of a stock, failure to meet listing standards, unregistered sales of securities, and material modifications to shareholder rights.1

An 8-K is required when a business changes accounting firms used for certification. Changes in corporate governance, such as control of the registrant or amendments to articles of incorporation, need to be reported. Changes in the fiscal year and modifications of the registrant's code of ethics must also be disclosed

If you dont think that NWBO's financial outlook changes if the trial were to fail then its very difficult to continue the conversation.

Legislation does not stipulate exactly that a one product biotech must disclose the failure of its only product. Now I'm incredibly busy but when I have time I will gladly provide some US citations. But I find the subject so incredibly logical that I am starting to have trouble continuing defending the obvious.